Relmada Therapeutics (RLMD) Other Non-Current Assets (2014 - 2026)
Relmada Therapeutics' (RLMD) quarterly Other Non-Current Assets came in at $19500.0 in Q1 2026, down 11.26% year-on-year from $21975.0 in Q1 2025, and little changed on a QoQ basis from $19500.0 in Q4 2025.
Relmada Therapeutics (RLMD) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 13 years of Other Non-Current Assets data on file, last reported at $19500.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 11.26% year-over-year to $19500.0 in Q1 2026; TTM through Mar 2026 was $19500.0, a 11.26% decrease from a year earlier, with the FY2025 full-year figure at $19500.0, down 11.26% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $19500.0, roughly flat from $19500.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for RLMD reached as high as $493452.0 in Q2 2023 and fell as low as $16095.0 in Q3 2022.
- Historically, Other Non-Current Assets has averaged $83825.3 across 5 years, with a median of $28293.0 in 2022.
- Across the five-year window, Other Non-Current Assets soared 2965.87% in 2023 and plunged 95.55% in 2024, its largest moves.
- Year by year, Other Non-Current Assets stood at $34875.0 in 2022, then gained by 23.66% to $43125.0 in 2023, then plunged by 49.04% to $21975.0 in 2024, then declined by 11.26% to $19500.0 in 2025, then changed by 0.0% to $19500.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $19500.0 in Q1 2026, $19500.0 in Q4 2025, and $21975.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - | 19,500.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19,500.00 |
| Dec 31, 2025 | 19,500.00 |
| Sep 30, 2025 | 21,975.00 |
| Jun 30, 2025 | 21,975.00 |
| Mar 31, 2025 | 21,975.00 |
| Dec 31, 2024 | 21,975.00 |
| Sep 30, 2024 | 21,975.00 |
| Jun 30, 2024 | 53,625.00 |
| Mar 31, 2024 | 43,125.00 |
| Dec 31, 2023 | 43,125.00 |
| Sep 30, 2023 | 493,452.00 |
| Jun 30, 2023 | 493,452.00 |
| Mar 31, 2023 | 34,875.00 |
| Dec 31, 2022 | 34,875.00 |
| Sep 30, 2022 | 16,095.00 |
| Jun 30, 2022 | 35,238.00 |
| Mar 31, 2022 | 28,293.00 |
| Dec 31, 2021 | 28,293.00 |
| Sep 30, 2021 | 25,000.00 |
| Jun 30, 2021 | 25,000.00 |